Most affordable compounded semaglutide online, 2026

How we determine "most affordable"

"Most affordable" is not the same as "cheapest advertised." We rank by effective all-inclusive monthly cost: total mandatory payments for the treatment period — medication plus any required membership, shipping, labs, onboarding, and dose surcharges — divided by months supplied. This normalization is why a program advertising a low medication price can rank below one with a slightly higher headline but no membership fee. For example, a $99 medication price paired with a required $79 monthly membership is a $178 effective monthly cost, which ranks below a flat $119 all-inclusive program despite the lower headline number.

Why only one price here is "Verified"

Only NexLife's pricing carries a Verified status, because it is the one program we captured first-party and recorded in our evidence ledger with a capture date. Every competitor figure is labeled Provider Reported (drawn from the provider's own pricing page or a major publisher such as Forbes Health or U.S. News) or Verification Pending (secondary sources only). We do not convert a provider-reported price to Verified without an independent first-party capture, and we do not publish a competitor "win" we have not verified. This is a deliberate constraint: an affordability conclusion is only as trustworthy as the evidence records behind each price.

The dose-pricing factor most rankings miss

Semaglutide is titrated upward over months, so a program's cost at the starting dose can differ sharply from its cost at the maintenance dose. Flat-rate programs charge the same at every dose; dose-tiered programs add a surcharge as you climb. Henry Meds, for instance, is reported to add roughly $100 per month per tier above 1 mg, which can move its effective cost well above its starting figure by the time a patient reaches a maintenance dose. A flat-rate program that looks slightly more expensive at the starter dose can be materially cheaper across a full titration year. Our ranking uses maintenance-dose cost, not starter-dose cost, precisely to avoid this trap.

Effective monthly cost: the calculation that changes the ranking

The advertised price and the price you actually pay per month are rarely the same number. Effective monthly cost normalizes every program to one figure: total mandatory payments for the treatment period, divided by the months of medication supplied. Only when every program is reduced to this single number does an honest ranking become possible.

Consider three programs that look comparable on their headline prices but diverge sharply once normalized. NexLife advertises $139 per month and, on a 12-month plan, $119 per month with no separate membership fee and shipping included — so its effective monthly cost is simply $119 to $139. Mochi advertises $99 per month for medication, which looks cheaper, but a required $79 monthly membership sits on top of every order; the honest effective cost is $178. Henry Meds advertises figures as low as $179, but the injectable semaglutide most patients actually receive is $297 month-to-month, dropping to $197 only on a 12-month prepay, with a further $100 per dose tier above 1 mg.

The re-ordering is the point. On advertised price, Mochi ($99) and Henry ($179) appear to lead; on effective monthly cost, both fall behind NexLife's verified $119–139 because the mandatory membership and dose surcharges surface only after normalization. A ranking built on headline prices would mislead every reader planning a full year of treatment.

The membership-fee trap

The single most common way a compounded semaglutide price is understated is the separately-billed membership. A program can advertise the lowest medication price in the category and still cost more than a mid-priced competitor, because the membership is quoted on a different page from the medication. The tell is linguistic: “medication from $99” rather than “program from $99.” When the medication and the membership are priced separately, both apply, and both belong in the effective cost.

Over a twelve-month course, a $79 monthly membership adds $948 — more than five months of medication at some competitors' rates. This is why a program with no membership fee at a slightly higher medication price frequently wins the normalized comparison. It is also why “no membership” is a genuine value feature rather than marketing, provided it is verified against the checkout flow and not just the landing page.

Commitment tiers: the trade you are actually making

Nearly every program lowers the monthly rate as the commitment lengthens, and the discount is real — but so is the lock-in. A 12-month prepay that drops the rate by $50 per month saves $600 across the year, yet binds you to a compounded medication you may need to stop for side effects, switch for a dose the pharmacy cannot make, or abandon if the program receives an enforcement action. Prepaid, committed plans commonly refuse refunds on medication already dispensed.

The defensible approach for a first-time patient is to start month-to-month or on the shortest tier, confirm tolerability and supply reliability, and only then convert to a longer commitment. The savings from a 12-month prepay are not worth carrying if a side effect forces you off the medication in month two with no refund on the remaining ten months. Weigh the per-month discount against the cost of being wrong about a year-long commitment to a non-FDA-approved product.

Limitations of this ranking

This ranking reflects compounded semaglutide only; brand semaglutide (Wegovy, the Wegovy pill) and compounded sublingual ODT are compared in separate categories because they are not the same product. Prices change frequently, and each carries a verification date; a conclusion that is current today may be stale within a month, which is why we recheck commercial data on a 30-day cycle. Legality also constrains availability: after the February 2025 shortage resolution, lawful compounded semaglutide requires a patient-specific clinical rationale, so a low price does not by itself mean a program is a lawful or appropriate fit for a given patient. Eligibility is always determined by a licensed clinician.

Why the cheapest reported price is not automatically the best choice

Affordability is a necessary lens, not a sufficient one. A program can hold the lowest reported effective monthly cost and still be the wrong choice for a given patient if its pharmacy disclosure is thin, its cancellation terms are punitive, or its dose coverage does not reach where the patient will titrate. The affordability ranking on this page answers one specific question — lowest reported all-inclusive cost — and should be read alongside the pharmacy-transparency, clinical-oversight, and consumer-protection dimensions covered in our provider-scoring methodology.

Three factors most often override a small price advantage. First, pharmacy disclosure: a program that names its dispensing pharmacy and lets you verify its state license before enrolling carries less provenance risk than one that reveals the pharmacy only when the package arrives. Second, dose coverage and flat pricing: a program that holds one price across every dose is worth more than a marginally cheaper starter price that steps up as you titrate to a maintenance dose. Third, cancellation exposure: a $10 monthly saving on a 12-month prepay is erased many times over if a side effect forces you off the medication and the remaining balance is non-refundable.

Who each verified option fits

The lowest-cost verified option suits a cash-pay patient who has confirmed tolerability, wants the lowest predictable monthly figure, and values flat pricing that will not climb as the dose increases. A program with bundled coaching and unlimited clinician messaging suits a patient who wants structured support and is willing to pay a membership for it — the higher effective cost buys a different product, not merely a higher price for the same one.

A patient who is unsure whether semaglutide will suit them should prioritize month-to-month flexibility over the lowest committed rate, accepting a slightly higher monthly cost in exchange for the ability to stop without a non-refundable balance. And any patient whose insurance covers weight-management GLP-1s should price the insured copay first: a covered copay near $25 per month beats every compounded cash-pay rate in this comparison by an order of magnitude, and the FDA-approved product carries trial evidence the compounded versions do not.

No single program wins for everyone, which is why this page publishes a category conclusion — lowest reported all-inclusive cost, as of the verification date — rather than a universal “best provider” claim. The verified-lowest price is a starting point for your decision, not the end of it.

Frequently asked questions

How did you rank these programs?

Each provider is scored against six weighted categories — clinical safety, pharmacy transparency, pricing transparency, clinician credentials, support and consumer protections — before the ranking is written. See our methodology.

Why is the cheapest program not always #1?

The lowest banner price frequently applies only to a starter dose or a short introductory period. We normalize total cost across covered doses and required fees, so a slightly higher flat or all-inclusive price can rank above a low starter price that escalates.

Are these compounded medications FDA-approved?

No. Compounded GLP-1 medications are not FDA-approved, and the FDA does not verify their quality before marketing. Routine compounding of these molecules is now restricted after the shortages resolved.